Endothelial stem cell therapy - Regen BioPharma

Drug Profile

Endothelial stem cell therapy - Regen BioPharma

Alternative Names: Aplastic anemia stem cell therapy - Regen BioPharma; Autologous stromal vascular fraction cells - Regen BioPharma; HemaXellerate I™; HemaXellerate™

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regen BioPharma
  • Developer Cascade LifeSciences; Pan American Cancer Treatment Center; Regen BioPharma
  • Class Stem cell therapies
  • Mechanism of Action Bone marrow cell stimulants; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Myelosuppression
  • No development reported Aplastic anaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Aplastic-anaemia in USA (Parenteral)
  • 24 Oct 2016 Updated efficacy data from a phase I trial in Myelosuppression released by Regen BioPharma
  • 16 Aug 2016 Interim efficacy data from a phase I trial in Myelosuppression released by Regen BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top